119 related articles for article (PubMed ID: 15685827)
1. Celecoxib and radiation therapy in non-small-cell lung cancer.
Gore E
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):10-4. PubMed ID: 15685827
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
3. Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.
De Ruysscher D; Bussink J; Rodrigus P; Kessels A; Dirx M; Houben R; Wanders R
Radiother Oncol; 2007 Jul; 84(1):23-5. PubMed ID: 17532073
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213.
Gore E; Bae K; Langer C; Extermann M; Movsas B; Okunieff P; Videtic G; Choy H
Clin Lung Cancer; 2011 Mar; 12(2):125-30. PubMed ID: 21550559
[TBL] [Abstract][Full Text] [Related]
5. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
Liao Z; Milas L; Komaki R; Stevens C; Cox JD
Am J Clin Oncol; 2003 Aug; 26(4):S85-91. PubMed ID: 12902863
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib: a novel treatment for lung cancer.
Abou-Issa H; Alshafie G
Expert Rev Anticancer Ther; 2004 Oct; 4(5):725-34. PubMed ID: 15485309
[TBL] [Abstract][Full Text] [Related]
7. [Cyclooxygenase 2 inhibitors and lung carcinoma].
Spano JP; Chouahnia K; Morère JF
Bull Cancer; 2004 May; 91 Suppl 2():S109-12. PubMed ID: 15899634
[TBL] [Abstract][Full Text] [Related]
8. Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.
Komaki R; Liao Z; Milas L
Semin Oncol; 2004 Feb; 31(1 Suppl 1):47-53. PubMed ID: 14981580
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Grimes KR; Warren GW; Fang F; Xu Y; St Clair WH
Oncol Rep; 2006 Oct; 16(4):771-6. PubMed ID: 16969492
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
Backhus LM; Petasis NA; Uddin J; Schönthal AH; Bart RD; Lin Y; Starnes VA; Bremner RM
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1406-12. PubMed ID: 16256796
[TBL] [Abstract][Full Text] [Related]
11. COX-2 inhibition and lung cancer.
Sandler AB; Dubinett SM
Semin Oncol; 2004 Apr; 31(2 Suppl 7):45-52. PubMed ID: 15179623
[TBL] [Abstract][Full Text] [Related]
12. Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy.
Socinski MA
Clin Lung Cancer; 2004 Mar; 5(5):274-89. PubMed ID: 15086966
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
14. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
Pisters KM; Evans WK; Azzoli CG; Kris MG; Smith CA; Desch CE; Somerfield MR; Brouwers MC; Darling G; Ellis PM; Gaspar LE; Pass HI; Spigel DR; Strawn JR; Ung YC; Shepherd FA; ;
J Clin Oncol; 2007 Dec; 25(34):5506-18. PubMed ID: 17954710
[TBL] [Abstract][Full Text] [Related]
15. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
16. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
Koch A; Bergman B; Holmberg E; Sederholm C; Ek L; Kosieradzki J; Lamberg K; Thaning L; Ydreborg SO; Sörenson S;
Eur J Cancer; 2011 Jul; 47(10):1546-55. PubMed ID: 21565487
[TBL] [Abstract][Full Text] [Related]
17. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
20. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
